daptomycin

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

1 headnote for daptomycin

- Daptomycin

398 documents for daptomycin

- No Sign of ANDA Filing for Daptomycin.
LEXINGTON, Mass. -- Cubist Pharmaceuticals (NASDAQ: CBST) said today that it believes that no generic manufacturer acted last September to secure a po...
- Business Wire
- March 13, 2008
- Positive Opinion For CUBICIN(R) (Daptomycin) Received from European Regulatory Authority; Final EU Approval of Antibiotic Expected in the First Quarter of 2006.
EMERYVILLE, Calif. & LEXINGTON, Mass. -- Chiron Corporation (Nasdaq:CHIR) and Cubist Pharmaceuticals Inc. (Nasdaq:CBST) today announced that the Commi...
- Business Wire
- November 17, 2005
- Safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Sponsored by Novartis. This multicenter, uncontrolled, nonrandomized, single group assignment study will evaluate the safety and efficacy of daptomyci...
- Journal of Drugs in Dermatology
- Vol. 8 Nbr. 1, January 2009

- Chiron and Cubist Pharmaceuticals Announce the Filing for EU Regulatory Approval to Market Cubicin -Daptomycin for Injection-.
EMERYVILLE, Calif. & LEXINGTON, Mass. -- Filing Moves CUBICIN Closer to EU Commercialization Chiron Corporation (Nasdaq:CHIR) and Cubist Pharmaceuti...
- Business Wire
- December 02, 2004
- CUBIST PARMACEUTICALS REVISES 2010 REVENUE GUIDANCE.
...net product revenues from CUBICIN (daptomycin for injection). The company now anticipates 2010 t...
- Biotech Financial Reports
- Vol. 18 Nbr. 1, January 2011
- Cubist Pharmaceuticals and Chiron Corporation Announce Plans to File for European Regulatory Approval of Cubicin --Daptomycin for Injection-- by Year-End 2004.
Business Editors/Health/Medical Writers BIOWIRE2K LEXINGTON, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--June 7, 2004 Cubist Pharmaceuticals, I...
- Business Wire
- June 07, 2004
- An Antibiotic to the Rescue
[...] Cubist's top management, including senior vice president and chief scientific officer Frank Tally, believed that the drug could help treat the increasing problem of Gram-positive resistant organisms, such as Staphylococcus aureus.

... licensed a drug from Eli Lilly called daptomycin, a first-in-class cyclic lipopeptide antibiotic ca...
- Scientist, The
- August 21, 2009
- Cubist Pharmaceuticals Settles CUBICIN Patent Litigation with Teva.
... grants Teva a license to sell generic daptomycin in US either as of June 24, 2018--if CUBICIN is gr...
- Business Wire
- April 04, 2011
- Cubicin (daptomycin) for the treatment of skin infections.
The Food and Drug Administration (FDA) recently approved Cubicin[TM] (daptomycin for injection) for the treatment of complicated skin and skin structu...
- Journal of Drugs in Dermatology
- Vol. 2 Nbr. 6, December 2003
- Daptomycin in the treatment of patients with renal insufficiency and complicated skin and skin structure infections.
Sponsored by Cubist Pharmaceuticals. This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharma...
- Journal of Drugs in Dermatology
- Vol. 5 Nbr. 8, September 2006